Protocol Number: 07-C-0138
Glioblastoma multiforme is a type of brain tumor whose growth is highly dependent on new blood vessels that grow in the tumor to nourish and support it. An experimental drug called GW786034 is believed to interfere with the formation of new blood vessels in tumors. Objectives: To determine whether GW786034 can slow tumor growth in patients with glioblastoma. To determine the safety profile of GW786034 in the treatment of malignant glioma patients. To characterize the pattern of changes of specific proteins associated with new blood vessel growth over time across patients. Eligibility: Patients 18 years of age and older with a glioblastoma who no longer benefit from standard treatment. Design: Patients take 800 mg of GW786034 a day by mouth in uninterrupted 28-day treatment cycles. Patients have the following procedures at specified intervals during treatment: -Physical examinations, including neurocognitive tests to determine the effect of the brain tumor on everyday living. -MRI scans of the head (imaging test using a magnetic field and radio waves) -PET scans of the head (imaging test using radioactive tracers) -Blood tests -Blood pressure monitoring twice a day at home. -Completion of a pill diary and a blood pressure diary. -Follow-up visits with the doctor
Search The Studies | Help | Questions |
National Institutes of Health Clinical Center |
||